CA2506231A1 - Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques - Google Patents
Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques Download PDFInfo
- Publication number
- CA2506231A1 CA2506231A1 CA002506231A CA2506231A CA2506231A1 CA 2506231 A1 CA2506231 A1 CA 2506231A1 CA 002506231 A CA002506231 A CA 002506231A CA 2506231 A CA2506231 A CA 2506231A CA 2506231 A1 CA2506231 A1 CA 2506231A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- independently
- atom
- composition
- carbon atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
D'une manière générale, l'invention concerne le traitement et/ou la prévention de la maladie d'Alzheimer, d'autres maladies neurodégénératives et/ou de maladies caractérisées par la présence de certains ions métalliques à l'aide de certaines compositions contenant des composés organosiliciés. Une composition selon l'invention peut être administrée à un mammifère, tel qu'un être humain. Dans certains cas, cette composition peut comprendre un silanol, un silandiol, un silantriol ou un organosilane cyclique et/ou former un silanol, un silandiol ou un silantriol lorsqu'elle est exposée à des conditions physiologiques, telles que celles qui se manifestent dans le sang, dans l'estomac et/ou dans le tractus gastro-intestinal ou dans le cerveau ou un autre organe. Dans certains cas, le composé organosilicié peut être lié à une fraction pouvant être transportée dans le cerveau à travers la barrière hémato-encéphalique, par exemple, un acide aminé, un peptide, une protéine, un virus, etc. Le composé organosilicié peut également être étiqueté (par exemple, par fluorescence ou radioamarqué) dans certains cas. Dans certains modes de réalisation, une composition ou une partie de celle-ci peut séquestrer de l'aluminium ou d'autres ions, par exemple, par liaison électrostatique avec des ions aluminium. Cette composition peut également présenter d'autres fonctionnalités, telles que des amines, certaines fractions alkyle et/ou aryle (notamment des alkyles et/ou des aryles substitués) ou des fractions hydrophobes, par exemple, pour faciliter le transport du composé organosilicié à travers la barrière hémato-encéphalique.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42720102P | 2002-11-18 | 2002-11-18 | |
US42710402P | 2002-11-18 | 2002-11-18 | |
US42720302P | 2002-11-18 | 2002-11-18 | |
US42710502P | 2002-11-18 | 2002-11-18 | |
US60/427,105 | 2002-11-18 | ||
US60/427,203 | 2002-11-18 | ||
US60/427,104 | 2002-11-18 | ||
US60/427,201 | 2002-11-18 | ||
US45634503P | 2003-03-20 | 2003-03-20 | |
US60/456,345 | 2003-03-20 | ||
USPCT/US03/36749 | 2003-11-17 | ||
US0336749 | 2003-11-17 | ||
PCT/US2003/037037 WO2004045552A2 (fr) | 2002-11-18 | 2003-11-18 | Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2506231A1 true CA2506231A1 (fr) | 2004-06-03 |
Family
ID=34382290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002506231A Abandoned CA2506231A1 (fr) | 2002-11-18 | 2003-11-18 | Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2006526567A (fr) |
AU (1) | AU2003298673A1 (fr) |
CA (1) | CA2506231A1 (fr) |
MX (1) | MXPA05005286A (fr) |
WO (1) | WO2004045552A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595308B2 (en) | 2002-11-18 | 2009-09-29 | Grenpharma Llc | Compositions for treating and/or preventing diseases characterized by the presence of metal ions |
WO2006028491A1 (fr) * | 2004-02-13 | 2006-03-16 | University Of Florida | Biocides a base de silanes et siloxanes a terminaison silanol |
US7960576B2 (en) | 2004-08-13 | 2011-06-14 | Momentive Performance Materials Inc. | Diol-derived organofunctional silane and compositions containing same |
US7928258B2 (en) | 2004-08-20 | 2011-04-19 | Momentive Performance Materials Inc. | Cyclic diol-derived blocked mercaptofunctional silane compositions |
WO2006047477A1 (fr) * | 2004-10-22 | 2006-05-04 | Grenpharama Llc | Compositions destinees a traiter et / ou prevenir des maladies caracterisees par la presence d'ions metalliques |
US7504456B2 (en) | 2006-02-21 | 2009-03-17 | Momentive Performance Materials Inc. | Rubber composition containing organofunctional silane |
US7919650B2 (en) | 2006-02-21 | 2011-04-05 | Momentive Performance Materials Inc. | Organofunctional silanes and their mixtures |
US7718819B2 (en) | 2006-02-21 | 2010-05-18 | Momentive Performance Materials Inc. | Process for making organofunctional silanes and mixtures thereof |
US7510670B2 (en) | 2006-02-21 | 2009-03-31 | Momentive Performance Materials Inc. | Free flowing filler composition based on organofunctional silane |
US8097744B2 (en) | 2006-08-14 | 2012-01-17 | Momentive Performance Materials Inc. | Free flowing filler composition comprising mercapto-functional silane |
US8008519B2 (en) | 2006-08-14 | 2011-08-30 | Momentive Performance Materials Inc. | Process for making mercapto-functional silane |
US8026108B1 (en) * | 2006-10-19 | 2011-09-27 | The University Of Central Florida Research Foundation, Inc. | Detection of biotargets using bioreceptor functionalized nanoparticles |
US7816435B2 (en) | 2007-10-31 | 2010-10-19 | Momentive Performance Materials Inc. | Halo-functional silane, process for its preparation, rubber composition containing same and articles manufactured therefrom |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4039666A (en) * | 1975-12-15 | 1977-08-02 | Dow Corning Corporation | Anticonvulsant phenylsilanes |
US5384312A (en) * | 1987-05-08 | 1995-01-24 | Merrell Dow Pharmaceuticals Inc. | Substituted silyl alkylene amines |
WO1993001819A1 (fr) * | 1991-07-15 | 1993-02-04 | Ethyl Corporation | Utilisation de composes a base de silicium dans la prevention de lesions traumatiques |
US5523295A (en) * | 1994-07-06 | 1996-06-04 | Brandeis University | Method for treating and preventing alzheimer's disease |
FR2725208B1 (fr) * | 1994-09-30 | 1996-11-29 | Exsymol Sa | Procede de preparation de composes de silicium biologiquement actifs sous forme concentree |
US5854215A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
JPH10101569A (ja) * | 1996-10-01 | 1998-04-21 | Eisai Co Ltd | 制酸剤 |
US5859277A (en) * | 1997-06-25 | 1999-01-12 | Wisconsin Alumni Research Foundation | Silicon-containing solid support linker |
-
2003
- 2003-11-18 WO PCT/US2003/037037 patent/WO2004045552A2/fr active Application Filing
- 2003-11-18 JP JP2004570636A patent/JP2006526567A/ja active Pending
- 2003-11-18 MX MXPA05005286A patent/MXPA05005286A/es not_active Application Discontinuation
- 2003-11-18 CA CA002506231A patent/CA2506231A1/fr not_active Abandoned
- 2003-11-18 AU AU2003298673A patent/AU2003298673A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA05005286A (es) | 2006-02-22 |
WO2004045552A2 (fr) | 2004-06-03 |
AU2003298673A1 (en) | 2004-06-15 |
JP2006526567A (ja) | 2006-11-24 |
WO2004045552A3 (fr) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice | |
CA2506231A1 (fr) | Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques | |
EP1061923B1 (fr) | Agents utilises pour traiter la maladie d'alzheimer | |
Dedeoglu et al. | Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis | |
Karr et al. | Cu (II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer’s disease amyloid-β peptide | |
US10113032B2 (en) | Amine functional polyamides | |
US8680077B2 (en) | Prochelators useful for inhibiting metal-associated toxicity | |
AU748768B2 (en) | Identification of agents for use in the treatment of Alzheimer's disease | |
Dellinger et al. | Inhibition of inflammatory arthritis using fullerene nanomaterials | |
US8273726B2 (en) | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | |
Kennedy et al. | Cellular lipid metabolism is influenced by the coordination environment of copper | |
JP6312806B2 (ja) | 抗菌薬耐性菌に対処するための組成物及び方法 | |
TW470644B (en) | Pharmaceutical compositions useful for inhibiting amyloid aggregation in a mammal | |
Nelson et al. | Development of novel silyl cyanocinnamic acid derivatives as metabolic plasticity inhibitors for cancer treatment | |
US20020037908A1 (en) | Methods and compositions for controlling protein assembly or aggregation | |
JP6122652B2 (ja) | プロテアソーム活性化剤 | |
Hernando-Gozalo et al. | Study of the antimicrobial activity of cationic carbosilane dendrimers against clinical strains of multidrug-resistant bacteria and their biofilms | |
US20180221321A1 (en) | Methods and products related to glutaminase inhibitors | |
EP1583765A2 (fr) | Compositions destinees au traitement et/ou a la prevention de maladies caracterisees par la presence d'ions metalliques | |
ZA200504054B (en) | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | |
US20090203644A1 (en) | Compositions for treating and/or preventing diseases characterized by the presence of metal ions | |
CN110121349B (zh) | 铋(iii)化合物及其方法 | |
US20240181023A1 (en) | Functionalized biocatalytical compositions | |
US20220401402A1 (en) | Compounds for preventing migration of cancer cells | |
WO2016023911A1 (fr) | Utilisation de l'acide 1,3-propane disulfonique ou de sels de celui-ci pour empêcher l'apparition de l'amyloïdose chez certaines populations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |